Biologics

Ocugen Reports Positive Phase 2 Data for Vision Loss Gene Therapy

Ocugen is announcing encouraging 12-month results from a mid-stage clinical trial of its experimental gene therapy OCU410, aimed at treating geographic atrophy, an advanced form of dry age-related macular degeneration that leads to irreversible vision loss.

According to the company, patients receiving the optimal dose of OCU410 in the Phase 2 ArMaDa trial experienced a 31% reduction in lesion growth compared to untreated controls, meeting statistical significance. The therapy also demonstrated signs of preserving retinal structure, with a 27% slower rate of photoreceptor degeneration, it says.

Ocugen says the results compare favorably to currently approved therapies, which have shown lesion growth reductions of approximately 15% at one year and 22% at two years. If confirmed in later-stage trials, OCU410 could represent a more effective option in a market where treatment choices remain limited.

Unlike existing drugs that require frequent injections — often six to twelve per year — OCU410 is being developed as a one-time gene therapy, potentially reducing the treatment burden that contributes to patient dropout in real-world settings.

The company notes that no serious adverse events linked to the therapy to date, and no cases of significant eye-related complications such as retinal detachment or inflammation.

Company executives say the results support advancing OCU410 into a Phase 3 registrational trial, expected to begin in the third quarter. The planned study could enroll up to 300 patients and will use an adaptive design to confirm efficacy and safety.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome